{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.2","upperLimit":"46.1","value":"30.2"},{"groupId":"OG001","lowerLimit":"27.7","upperLimit":"59.0","value":"42.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"PDIR is defined as percentage of participants who meet any of following criteria occurring within 6 months of start of treatment. a) CRAB criteria: true progression events, b) Serum M-protein: increase by 25 % compared with baseline at 2 consecutive assessments, c) Magnetic resonance imaging: unequivocal increase in focal bone lesions, d) Immunoparesis: decrease by 25% compared with baseline of 2 other non-affected immunoglobulin (Ig) (IgG, IgM, IgA) at 2 consecutive assessments, e) Hemoglobin: decrease of 1.5 g/dL (with at least 1 read below LLN) at 2 consecutive assessments, with no other identifiable cause. PD is defined as presence of M-component in serum plus clonal plasma cells in bone marrow plus 1 or more of following: Calcium elevation (\\> 11.5 mg/dL \\[\\> 2.88 mmol/L\\]); Renal insufficiency (creatinine \\>2 mg/dL \\[177 micro mol/L or more\\]); Anemia (hemoglobin \\<10 or 2 g/dL lower than LLN) \\[hemoglobin \\< 6.5 or 1.25 mmol/L lower than LLN\\]); Bone disease (lytic lesions or osteopenia).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 15 milligram per kilogram (mg/kg) of siltuximab as a 1-hour intravenous (IV) infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG000","title":"Siltuximab"},{"description":"Participants received placebo as a 1-hour IV infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Response evaluable population included participants who had a diagnosis of high-risk smoldering multiple myeloma (SMM) and received at least 1 dose of siltuximab/placebo treatment. In addition, participants were to have at least 1 post-baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"At 6 Months","title":"Progressive Disease Indicator Rate (PDIR) at 6 Months","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}